Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Start-up Spotlight: Cloud Pharmaceuticals
Posted on October 28th, 2016 by Betsy Davis in Pharma R&D
This week we are focusing on Cloud Pharmaceuticals, a drug design and development company that utilizes cloud computing in its work. Don Van Dyke, Chief Operating Officer of Cloud Pharmaceuticals, provides some insight into his company’s fascinating work.
Briefly describe your company’s mission and approach.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Our approach amplifies the power of cloud computing and artificial intelligence (AI) to radically improve drug discovery and design.
Tell us more about your work.
Our proprietary design process combines AI and cloud computing to search virtual molecular space and design novel drugs. These drugs are excellent candidates for further development and have novel composition of matter IP. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. We partner at all stages of drug development, from discovery through to clinic, and are building an extensive product pipeline that spans a wide range of indications.
What impact will this research have?
Before long, most drugs will be designed by computer using artificial intelligence, machine learning, big data, and computational chemistry. Cloud Pharmaceuticals’ long-term mission is to be a leader in the transition from discovery to design, and, in the process, to amass a portfolio of valuable intellectual property rights in drug molecules that it designs. Our vision is to provide better, faster, and less expensive development of novel medicines to support the next generation of cures and treatments. We will enable personalized medicine by making it possible to design a drug especially targeted for small populations of patients.
Why is this important right now?
We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance. We are about to enter the age of designed drugs. Soon, all drugs will be designed rather than found. Designed drugs may be similar to discovered natural compounds, which will continue to give scientists clues about how nature and evolution have shaped biological interactions. But deeper understanding of the molecular basis for disease will bring about targeted attacks on the functioning of the very molecules that make us sick.
What will the next steps for the company be?
Cloud completed design programs against 17 drug targets in 2015. Along with further developing these assets, the company will continue to expand its portfolio of completely novel active drug molecules against as many targets as possible.
Are you currently looking for partners or investment?
Cloud is currently raising a $10 million round of financing. The company is always in search of new design and development partners of all sizes.
Here’s what just one of the company’s partners has to say about working with them:
“Our partnership with Cloud Pharmaceuticals has worked well. They have generated completely novel compounds for several targets that are more potent than any other known inhibitors.”
Robert Hromas, MD, FACP
Chair and Professor
Department of Medicine
University of Florida Health
Cloud SAB member
To get in contact with Don Van Dyke, or to follow Cloud Pharmaceuticals online:
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Strategic Marketing Manager
- Big Data vs. Infectious Disease
- Pharma Companies United By a Need for Common Data Models
- Snakes (aka Chutes) and Ladders – failures and opportunities
- Big Data and Proactive Pharmacovigilance
- Artificial Intelligence Comes to the Life Sciences